This document is an investor presentation for Aurobindo Pharma Limited's unaudited financial results for the first quarter ended June 30, 2026 (Q1FY27), submitted to the National Stock Exchange of India Limited and BSE Limited under regulatory disclosure requirements.

Q1FY27 Financial Performance

Revenue & Profitability:

  • Revenue from Operations stood at ₹9,150 Cr, a growth of 16.3% Year-on-Year (YoY) from ₹7,868 Cr in Q1FY26 and 3.4% Quarter-on-Quarter (QoQ) from ₹8,853 Cr in Q4FY26.
  • Gross Profit was ₹5,523 Cr (Gross Margin: 60.4%), up 19.3% YoY from ₹4,629 Cr (58.8% margin).
  • Operating EBITDA (before Forex and Other Income) was ₹1,924 Cr (EBITDA Margin: 21.0%), representing 20.0% YoY growth from ₹1,603 Cr (20.4% margin).
  • A one-time expense of ₹43 Cr was recorded on account of the derecognition of a lease receivable.
  • Profit After Tax (PAT) attributable to owners was ₹1,033 Cr, up 25.2% YoY from ₹825 Cr.
  • Reported EPS was ₹17.86, up 25.8% YoY from ₹14.20.
  • The average USD/INR exchange rate for the quarter was 94.53.

Cash Flow & Debt Position:

  • The company generated Free Cash Flow from Business of US$98 million during the quarter.
  • Net Capex was US$78 million, allocated towards capability enhancements and new business developments.
  • Major outflows included US$247 million for the acquisition of Lannett and US$85 million for a buyback.
  • The company maintained a strong net cash position (including investments) of ~US$42 million as of June 30, 2026.
  • Gross Debt stood at US$887 million (₹8,393 Cr restated in INR), with a finance cost of 4.8%.

Business Segment Performance

Formulations Business (₹8,101 Cr, 88.5% of revenue):

  • USA: Revenue was ₹3,770 Cr, accounting for 41.2% of consolidated revenue. It grew 8.1% YoY and 6.4% QoQ. Growth was driven by volume gains and new launches; 10 products were launched in the quarter.
  • Europe: Revenue was ₹2,937 Cr, up 25.6% YoY.
  • Growth Markets: Revenue was ₹1,063 Cr, up 37.7% YoY. This includes domestic sales of ₹104 Cr.
  • ARV: Revenue was ₹330 Cr, down 6.9% YoY, accounting for 3.6% of revenue.

API Business (₹1,049 Cr, 11.5% of revenue):

  • Total API revenue grew 14.6% YoY.
  • Beta-lactam API revenue was ₹800 Cr (up 25.7% YoY).
  • Non Beta-lactam API revenue was ₹250 Cr (down 10.6% YoY).

Regulatory & Product Updates

  • Received final approval for 10 products in the US market during the quarter.
  • The total US ANDA pipeline as of June 30, 2026, consists of 896 filings: 737 Final Approvals, 33 Tentative Approvals, and 126 under review.

Biosimilars and Biologics CMO Update (CuraTeQ Biologics)

Regulatory & Filings:

  • Secured ANVISA GMP certification for Drug Substance and Drug Product facilities.
  • Filed Denosumab (FILVIZY and FUGEVY) with CHMP/EMA.
  • EMA filing for Omalizumab is on track for Q3 FY27.
  • First U.S. FDA filings for Omalizumab, Denosumab, and Bevacizumab are planned for 2026.

Commercial Expansion:

  • All four MHRA-approved products (Bevqolva, Dazublys, Zefylti, Dyrupeg) are supplying commercially in the UK.
  • Commercial supplies have commenced in multiple European countries and Mexico.
  • Distribution agreements were secured with STADA (EU) and Orion (Nordics).
  • Strategic partnerships were established for entry into Algeria and Uzbekistan.

Pipeline & Capacity:

  • The biosimilars pipeline includes assets in oncology, respiratory, autoimmune, and ophthalmology, with multiple products launched, filed, or in development.
  • A capacity expansion of 10,000 L (4 × 2,500 L) mammalian cell-culture bioreactors is underway.
  • The merger of AuroVaccines into CuraTeQ is targeted for completion by March 2027.
  • Investment is ongoing in new modalities like subcutaneous formulations and device-combination products.

Biologics Contract Manufacturing (TheraNym)

  • Unit 1 was inaugurated on June 3, 2026; qualification activities are scheduled to begin in November 2026.
  • Ground-breaking for the greenfield Unit 2 (Drug Substance facility) is complete; full-scale construction begins October 2026, pending clearances.
  • Unit 2 will add 60 kL of bioreactor capacity at an estimated capex of US$180 Mn, targeting qualification readiness in 2030.
  • TheraNym is anchored by a long-term partnership with Merck Sharp & Dohme (MSD).